Clinical trials: Hepatitis A Virus
HIV 1 Infection, HIV 2 Infection
A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
The objectives of this study are as follows: To evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care…
- Conditions
- HIV 1 Infection, HIV 2 Infection, Syphilis Infection, Hepatitis B Infection
- Trial name
- NCT07563309
- Testing
- TruPlex HIV/HepB/Syphilis Rapid Test
- Where
- 3 sites in South Africa
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Hepatitis C Patients
Immune Dysregulation in Hepatitis C Patients With or Without Arthritis
The purpose of this study is to study the role of the Immune System in causing arthritis in patients with Hepatitis C.
- Trial name
- NCT01195987
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
Hepatitis B
Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers
The purpose of this study is to evaluate the persistence of anti-hepatitis B surface antigen (anti-HBs) antibodies 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine.
- Trial name
- NCT00240500
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Liver Cancer, Hepatitis B
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma
Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection.
- Conditions
- Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver
- Trial name
- NCT00767936
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Stanford University
Hepatitis C, Chronic
Directly Observed Therapy for HCV in Chennai, India
The primary objective of this pilot trial is to evaluate the feasibility of 12 weeks vs. 24 weeks of field-based directly observed therapy (DOT) for HCV therapy in a resource-limited setting.
- Trial name
- C-DOT (NCT02541409)
- Testing
- Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Chronic Hepatitis C
Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C
The number of hemodialysis patients with chronic renal failure in Japan exceeds 0.3 million and is showing an increasing trend. The rate of infection with hepatitis C virus (HCV) is high in hemodialysis patients, and it has been…
- Trial name
- NCT03022006
- Testing
- elbasvir, grazoprevir
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Norte Study Group
Hepatitis C Virus (HCV)
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
- Trial name
- NCT07419347
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AbbVie
Viral Hepatitis B, Viral Hepatitis C
Therapeutic Option for Hepatitis B and C: a French Cohort
The cohort will integrate clinical, genetic, pharmacogenomics, environmental, biomarkers and behavioral data in a large number of patients and will be a leading equipment for crossdisciplinary and translational research on…
- Trial name
- HEPATHER (NCT01953458)
- Where
- France
- Volunteers
- 20,902 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
Identification of Hepatitis C Virus (HCV) Specific T Cells
Nearly 175 million people worldwide are infected by Hepatitis C Virus (HCV), close to 3% of the global population. Contrary to other chronic infections such as HIV, clearance of HCV is possible.
- Trial name
- TETRA (NCT01534728)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hepatitis C Virus Infection
Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women
This is a prospective, observational, open-label, pharmacokinetic study will evaluate PK of SOF/DAC in lactating HCV-infected females at weaning or women who voluntarily decided to forego breastfeeding to initiate HCV infection…
- Trial name
- NCT04852614
- Testing
- Pharmacokinetic test
- Where
- Egypt
- Volunteers
- 10 people
- Sponsor
- Ain Shams University
Hepatitis C
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients…
- Trial name
- RHACE 1 (NCT02098616)
- Testing
- DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Timothy Morgan, MD
HCV
TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers
The purpose of this study is to evaluate the safety and tolerability of three different doses of TMC435350 compared to placebo in healthy Japanese males.
- Trial name
- NCT00752544
- Testing
- TMC435350
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Combined Point of Care Diagnostic of HIV, HBV and HCV
Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C
Prospective, cross-sectional, adaptative study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA IBC (a Multiplex Point-of-Care Test for the detection of HIV, HBV and HCV) in detecting anti-HIV…
- Trial name
- MAGICIEN (NCT06082336)
- Testing
- MagIA IBC test in capillary blood, MagIA IBC test in other blood matrices
- Where
- 2 sites in France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- MagIA Diagnostics
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
HIV and Hepatitis B Coinfection
TAF for HIV-HBV With Renal Dysfunction
The investigators aim at describing changes in renal glomerular and tubular function with after the switch from TDF to TAF in HIV/HBV-coinfected patients with mild to moderate renal dysfunction and to assess the virological…
- Trial name
- NCT03115736
- Testing
- Tenofovir Alafenamide
- Where
- 8 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Rift Valley Fever
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy…
- Trial name
- NCT06925919
- Testing
- IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- IDBiologics, Inc.
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Chronic Hepatitis B Infection
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03209011
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yao Xie
HEPATITIS B CHRONIC
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
- Trial name
- ELIMINATE-B (NCT06680232)
- Testing
- PBGENE-HBV
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 45 people
- Sponsor
- Precision BioSciences, Inc.
Hepatitis C Virus Infection, Response to Therapy of
Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection
This 4-year project will be guided by a biobehavioral model for the study of exercise interventions in two phases with the purposes to : 1.
- Trial name
- NCT01572233
- Testing
- Personalized Physical Activity and Psycho-Education (PPAPE) Program
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.